Bringing effective new treatments and options to the patients who need them.

Creating Innovative Therapies that Eradicate Disease and Increase Healthspan - Lamorinda Therapeutics is focused on advanced cell therapy solutions targeting acute and chronic conditions, including cancer, autoimmune disorders, and age-related degeneration, enhancing cellular performance and empowering the body’s natural healing processes. www.lamorindatx.com

California Shakespeare Theater (CAL SHAKES) redefines the classical theater for the 21st Century, making works of extraordinary artistry that engage with our contemporary moment so we might learn about ourselves and each other in the fullness of our world.

Executive and Corporate Officer responsible for a clinically- and commercially-focused cell therapy and degenerative disease products organization managing Human Resources, Business Development, Alliance Management, Strategic and Corporate Planning, Technical Operations, Global Program and Portfolio Management, Facilities and Engineering, and Enterprise IT.Key highlights include:• Responsible for translating corporate strategy into actionable goals for performance and growth.• Leads the corporate goals-setting process, performance management and annual operational planning.• Functions under direct management include strategic and corporate planning, business development, alliance management, strategy, human resources, global program strategy, portfolio and project management, technology platform development, process development, clinical and commercial manufacturing, supply chain, quality and compliance, CMC program management, business operations, enterprise facilities and engineering and enterprise IT.

Executive and Corporate Officer responsible for a clinically- and commercially-focused cell therapy and degenerative disease products organization managing all aspects of Global Program and Portfolio Management, Technical Operations, Enterprise Facilities and Engineering, and Enterprise IT.Key highlights include:• Enterprise leader responsible for a >300 FTE organization delivering clinical and commercial cell therapy and tissue products.• Successful advancement of pipeline assets through regulatory milestones in both cell therapy and degenerative disease platforms. • Responsible for rapid and effective scaling of the entire CTO organization to achieve key clinical milestones and to grow commercial supply of tissues products.• Leads the organization responsible for the development and commercialization of Celularity’s allogeneic CAR-T (CYCART-19) and NK (CYNK-001, CYNK101) cell therapy platforms across hematological and solid tumors.• Responsible for supporting the advancement of Celularity’s innovative exosome pipeline focused on applications in regenerative and age-related diseases at the pre-clinical stage.• Responsible for development support and commercial supply of the company’s tissue-derived therapies BIOVANCE®, BIOVANCE®•3L Ocular, and Interfyl®.• Accountable for supporting the development and commercialization of the company’s 510K products across degenerative disease indications.

Executive responsible for a cell therapy organization managing Kite global corporate strategy, product & program management, pipeline and portfolio planning, transformation management office and global business operations.Key highlights include:• Global leader responsible for developing Kite’s scalable and effective corporate strategy and corporate program and portfolio management.• Managed senior-level direct reports and broad organization with global accountability.• Led the organization that reshaped Kite’s portfolio governance and product team operating model.• Managed organization that leads cross-functional product teams including YESCARTA® (axicabtagene ciloleucel), TECARTUS™ (brexucabtagene autoleucel), clinical programs including KITE-718 (MAGE A3/A6), KITE-439 (HPV16 E7) and additional innovative therapies.• Experience leading organizations through product life-cycle milestones including go/no-go decisions, IND, BLA, MAA and other regulatory filings.• Led the organization in the establishment of strategic priorities, performance goals and KPIs in the near-, mid- and longer-term horizon.• Responsible for the establishment and maintenance of Kite’s cell therapy commercialization framework and stage gates.• Responsible for the creation and deployment of the operational excellence program, project management, and change management centers of excellence within the company.

Executive responsible for a cell therapy operations organization managing global strategic planning and portfolio management, CMC program management, alliance management, corporate engineering and facilities.Key highlights include:• Global leader responsible for developing scalable and effective operations strategy to enable launch and commercial milestones.• Managed 5 senior-level direct reports and was responsible for building and scaling a >140 employee organization with US and Ex-US responsibility.• Led the organization to develop and implement Kite’s global manufacturing and supply strategy, viral vector platform development/manufacturing strategy and the next-generation manufacturing and automation strategy. • Leader on joint venture, licensing and partnering deal teams representing all aspects of international Technical Operations business planning and implementation.• Accountable for an organization leading CMC program management that drives cross-functional team leadership of pipeline products from R&D through commercialization.• CMC program management and lifecycle leadership for Kite’s commercial products and pipeline including YESCARTA® (axicabtagene ciloleucel), multiple myeloma and solid tumor programs.• Accountable for alliance management with key external corporate partners and international alliances.• Responsible for a >$200M capital portfolio encompassing project initiation through hand-over and commissioning.• Accountable for Kite facility operations with >300,000 sqft under management, including office, R&D laboratory and clinical & GMP manufacturing space.• Accountable for EHS&S, transportation, commuter programs, real estate management across all Kite functions

Global business executive responsible for leading the integration of Roche’s ~$1.2B in acquisitions for the Diagnostics Sequencing business through close-out and ongoing alliance management. Represents Roche as the point person with the partner company CEO or executive leaders ensuring quality communication between the companies and successful internal value creation. Key highlights include:• Successful integration of acquired companies via cross functional management, coaching, network building, navigating joint interactions, issue resolution, alignment on business priorities and integration into SeqU portfolio for regular governance.• Key member of the business development team enabling the “Want, Find, Get, Manage” process to identify transformational technologies and incorporate them into the Roche personalized healthcare value stream.• Cross-platform expertise in the areas of sample preparation, next-generation sequencing (NGS), analytics, and medical content development.• Led the process to successfully integrate partner company functions across Roche R&D, technical operations, commercial, HR, legal, finance and procurement, IT, regulatory and quality groups.• Fully accountable for financial and non-financial aspects of contract execution including commercial and R&D milestone payments to shareholders, escrow and hold-back, and shareholder communications.

Site leader responsible for operations including supply chain management, manufacturing plant strategic and capacity planning, production materials planning, inventory and warehousing materials management, site technical training, environmental health, safety, security, procurement, operational excellence, strategic business planning, IT, launch capability readiness, inspection readiness support. Key highlights include:• Managed 9 senior-level direct reports and was responsible for a >100 employee organization.• Organization restructuring while increasing employee engagement by 11% within first year (exceeding Group benchmark).• Drove operational efficiencies and procurement cost savings (>$500k annually).• Increased the performance of metrics and KPI reporting across all functions.• Reduced headcount growth projections by 60% through robust strategic workforce planning.• Initiated Launch Capability Program to enable tech transfer of pipeline while ensuring optimal commercial performance.• Drove innovation across the organization and implemented a self-directed team in material operations.

Network leader responsible for enabling strategy definition and implementation across the biologics network.Key highlights include:• Global program leader responsible for >$250 M investment decisions for internal/external manufacturing and development.• CMC global project leader developing launch strategies, business processes and implementation plans for the end-to-end supply chain (pipeline through commercialization).• Leader of late stage drug substance & pipeline strategy and member of biologics drug substance technology council.• Pharma Biologics operation unit leader responsible for affiliate negotiation, insourcing and supply agreements.

International assignment based at the Roche Corporate Headquarters in Basel Switzerland with the responsibility for biologics and small molecule product forecasting, manufacturing and supply chain strategy.Key highlights include:• Supported new product launches and market analysis.• Clinical and commercial support for drug substance, drug product and packaging.• Enabled launch readiness and support of ongoing clinical programs.• Developed sales models including cross-product cannibalization, pricing elasticity, patient uptake and probability of launch assumptions.

Strategic program leader and organizational change agent collaborating with key stakeholders to deliver scalable, efficient, sustainable, and cross-functional solutions in support of the network’s business needs.Key highlights include:• Developed and implemented a network wide capacity planning strategy (PT Capacity Strategy Agility Targets).• Developed the site business plan and network plan for the biologics network.• Member of global teams targeting improvements for GMP end-to-end reliability (TIGER).• Business process owner for the biologics network strategic workforce planning process (size, shape and skills).• Global Roche site partnering and development of business plans and network strategies.

Management of the International Sales and Collaborations (Ex-US) division P&L with responsibilities for $1 B in annual product revenue.Key highlights include:• Managed direct reports in strategic project execution and the Global stewardship of 30 cost centers across multiple cost bases with forecasting, budgeting and monthly close responsibilities.• Global currency exchange rate risk mitigation, Procurement buy plan modeling and vendor selection strategies.• FP&A, long range planning and consolidation, Engineering project expense and capital.• Roche global initiatives including P&L savings tracking and Operational Excellence (GEC presentation).• Project support resulting in corporate cost reductions.• Joint steering committee member overseeing 3rd Party relationships.

Involved in all aspects of Ex-US product manufacturing and transfer sales across 10 product categories, 21 configurations and 7 international customers.Key highlights include:• Negotiated settlements and contracts with external suppliers and partners.• Drove key improvements in revenue analysis, transfer price accounting, setting annual product pricing, determining work-wide demand to enable manufacturing network optimization and supply chain efficacy.• Responsible for all aspects of financial management including budgeting, forecasting and month-end close.

Responsible for developing corporate quarterly and annual forecast by coordinating with senior executives, marketing, sales and finance teams.Key highlights include:• Analyzed and monitored business performance and trends to drive strategic and tactical business decisions.• Built robust customer utilization, market behavior and manufacturing models.• Performed analysis and generated reports regarding product trends, ordering patterns and pricing using data collected from internal systems and external sources.• Performed analysis and generated reports regarding customer install base and buying behavior.• Profiled and reported on competitor activity through analysis of competitive intelligence data collected through external sources and information gathered by the commercial team.• Identified and recommended potential market opportunities, product line expansions and/or new product opportunities.

Responsible for managing the inflow of all investment opportunities, performing due diligence on potential investments and recommending top leads to executive management.Key highlights include:• Analyzed the scientific merit, financial standing and the strength of investment prospects.• Led weekly cross-functional team meetings and presented new investment opportunities to corporate development, legal and finance senior management.• Worked closely with board of directors and corporate licensing to maximize the utility of all investment prospects.• Supported investment sourcing process and monitored developments and performance of portfolio companies.

Responsible for the development of a strategic approach to identify personalized health care opportunities for the executive committee.Key highlights include:• Using several data and information mining resources, successfully developed a stepwise process to select and screen for companion diagnostic drug candidates and determine the utility of relevant biomarkers.• Conducted interviews with physician specialists and clinical trial sponsors to identify potential under-performing or sub-optimal therapies which could benefit from a diagnostic.• Independently identified new market opportunities for Biosite and initiated a pilot study with a strategic corporate partner, local hospital and physician sponsor.• Designed and developed marketing literature for ongoing and new products.

FESF is a 501c3 non-profit corporation that funds college scholarships to underprivileged youth.

- Investigator in Tjian Laboratory- Research focussing on gene regulation and oncology targets- Secured research funding through competitive grant writing